Lihe Su

USPTO Granted Patents = 8 (Patent Applications = 3)

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 64(Granted Patents)

Company Filing History:

Biogen International Neuroscience Gmbh

where one patent can have more than one assignee

Years Active: 2012-2019

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10301381 - Anti-alpha synuclein binding molecules (2019-05-28),

2. 9975947 - Anti-alpha synuclein binding molecules (2018-05-22),

3. 9580493 - Anti-α synuclein binding molecules (2017-02-28),

4. 9321840 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2016-04-26),

5. 9297810 - CD40L-binding agent based platelet aggregation assays (2016-03-29),

6. 8784823 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2014-07-22),

7. 8409810 - Platelet aggregation assays using a CD40L-binding agent (2013-04-02),

8. 8293237 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2012-10-23),

Title: The Innovative Contributions of Lihe Su

Introduction

Lihe Su is a prominent inventor based in Reading, MA (US), known for his significant contributions to the field of biotechnology. With a total of 8 patents to his name, he has made remarkable strides in developing therapeutic solutions targeting neurodegenerative diseases.

Latest Patents

Among his latest innovations are the anti-alpha synuclein binding molecules. These molecules are specifically designed to bind to human α-synuclein, which is crucial in the context of neurodegenerative disorders. The patents detail methods for creating antibodies or antibody-binding fragments that target specific N-terminal and C-terminal epitopes on human α-synuclein. These binding molecules hold promise for use in pharmaceutical and diagnostic compositions aimed at α-synuclein targeted immunotherapy and diagnosis.

Career Highlights

Lihe Su has had a distinguished career, working with notable companies in the biotechnology sector. He has been associated with Biogen Idec MA Inc. and Biogen International Neuroscience GmbH, where he has contributed to groundbreaking research and development efforts.

Collaborations

Throughout his career, Lihe Su has collaborated with esteemed colleagues, including Yen-Ming Hsu and Linda C. Burkly. These partnerships have fostered innovation and have been instrumental in advancing their shared research goals.

Conclusion

Lihe Su's work exemplifies the spirit of innovation in biotechnology, particularly in the development of therapies for neurodegenerative diseases. His contributions continue to impact the field significantly, showcasing the importance of targeted immunotherapy in modern medicine.

This text is generated by artificial intelligence and may not be accurate.